Idorsia Ltd IDRSF
4.95 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
4.40 Day range 4.40
3.82 52-week range 8.19
- YTD
- -5.71%
- 1 year
- +12.50%
- Market cap
- 1.34B
- EPS (ttm)
- -1.74
- YTD return
- -5.71%
- 1-year return
- +12.50%
- Volume
- 250
- Avg volume
- 1.60K
- Open
- 4.40
- Previous close
- 4.95
- Day's range
- 4.40 – 4.40
- 52-week range
- 3.82 – 8.19
- Earnings date
- Oct 29, 2026
2Y +3.86 (+354.13%)
Next earnings
Oct 29, 2026
Expected Oct 29, 2026. Consensus EPS estimate -0.33437.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 30, 2026 | -0.33437 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | -0.24123 | -0.20412 | +0.04 | +15.38% |
| Apr 28, 2026 | Mar 31, 2026 | -0.23148 | -0.17518 | +0.06 | +24.32% |
| Feb 26, 2026 | Dec 31, 2025 | -0.24597 | -0.34058 | -0.09 | -38.46% |
| Oct 30, 2025 | Sep 30, 2025 | -0.27621 | -0.34526 | -0.07 | -25.00% |
| Jul 30, 2025 | Jun 30, 2025 | -0.25208 | -0.07603 | +0.18 | +69.84% |
News
Idorsia Ltd (IDRSF) Q2 2026 Earnings Call Transcript 
Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon 
Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology 
New analysis of Idorsia's aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension 
Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2026 
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year 
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders 
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development 
Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders Transcript 
Idorsia announces the nomination of three candidates for election to the Board of Directors
Your note
Sign in to keep a note on IDRSF — it syncs with the Stock Master app.